AMEX:ISR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Isoray's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ISR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.9%

ISR

-1.2%

US Biotechs

-1.1%

US Market


1 Year Return

23.7%

ISR

30.7%

US Biotechs

15.6%

US Market

Return vs Industry: ISR underperformed the US Biotechs industry which returned 30.7% over the past year.

Return vs Market: ISR exceeded the US Market which returned 15.6% over the past year.


Shareholder returns

ISRIndustryMarket
7 Day-4.9%-1.2%-1.1%
30 Day-30.2%1.3%4.2%
90 Day-42.8%-2.5%6.3%
1 Year23.7%23.7%33.0%30.7%18.2%15.6%
3 Year-16.4%-16.4%19.6%13.6%39.6%30.4%
5 Year-73.9%-73.9%8.7%1.0%79.5%59.2%

Price Volatility Vs. Market

How volatile is Isoray's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Isoray undervalued compared to its fair value and its price relative to the market?

4.58x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ISR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ISR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ISR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ISR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ISR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ISR is overvalued based on its PB Ratio (4.6x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Isoray forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

56.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ISR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ISR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ISR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ISR's revenue (24.4% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: ISR's revenue (24.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ISR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Isoray performed over the past 5 years?

-0.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ISR is currently unprofitable.

Growing Profit Margin: ISR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ISR is unprofitable, and losses have increased over the past 5 years at a rate of 0.7% per year.

Accelerating Growth: Unable to compare ISR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ISR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: ISR has a negative Return on Equity (-60.21%), as it is currently unprofitable.


Next Steps

Financial Health

How is Isoray's financial position?


Financial Position Analysis

Short Term Liabilities: ISR's short term assets ($5.5M) exceed its short term liabilities ($1.6M).

Long Term Liabilities: ISR's short term assets ($5.5M) exceed its long term liabilities ($1.4M).


Debt to Equity History and Analysis

Debt Level: ISR is debt free.

Reducing Debt: ISR has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ISR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ISR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 6.3% each year


Next Steps

Dividend

What is Isoray current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ISR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ISR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Lori Holmes-Woods (58 yo)

2.33yrs

Tenure

US$491,637

Compensation

Ms. Lori A. Holmes-Woods has been Chief Executive Officer since December 12, 2018 and its Director at IsoRay, Inc. since June 4, 2018 and served as its Interim Chief Executive Officer since June 4, 2018 un ...


CEO Compensation Analysis

Compensation vs Market: Lori's total compensation ($USD491.64K) is about average for companies of similar size in the US market ($USD585.94K).

Compensation vs Earnings: Lori's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Lori Holmes-Woods
CEO & Director2.33yrsUS$491.64k0.62%
$ 206.4k
Michael Krachon
Executive Vice President of Sales & Marketing4.58yrsUS$345.14k0.12%
$ 39.9k
William Cavanagh
Chief Research & Development Officer1.67yrsUS$318.02k0.023%
$ 7.6k
Jonathan Hunt
CFO & Co-Principal Financial Officer1.83yrsUS$166.02kno data
Jennifer Streeter
COO & VP of Human Resources1.25yrsno data0.0062%
$ 2.1k
Mark Austin
Controller3.25yrsno data0.018%
$ 6.1k
Krista Cline
Senior Director of Operations & Corporate Secretaryno datano data0.026%
$ 8.7k

2.1yrs

Average Tenure

50yo

Average Age

Experienced Management: ISR's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lori Holmes-Woods
CEO & Director2.33yrsUS$491.64k0.62%
$ 206.4k
Michael McCormick
Independent Chairman of the Board2.33yrsUS$52.84k0.025%
$ 8.4k
Philip Vitale
Independent Director6.75yrsUS$52.84k0.13%
$ 41.8k
Alan Hoffmann
Independent Director4.75yrsUS$52.84k0.052%
$ 17.1k

3.5yrs

Average Tenure

59yo

Average Age

Experienced Board: ISR's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.4%.


Top Shareholders

Company Information

Isoray, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Isoray, Inc.
  • Ticker: ISR
  • Exchange: AMEX
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$33.181m
  • Shares outstanding: 87.23m
  • Website: https://isoray.com

Number of Employees


Location

  • Isoray, Inc.
  • 350 Hills Street
  • Suite 106
  • Richland
  • Washington
  • 99354
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ISRAMEX (NYSE MKT LLC)YesCommon StockUSUSDAug 2005

Biography

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the Unit ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 00:40
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.